|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
1/7/2010 9:07:53 AM
SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (Nasdaq: ZGEN) today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000. ZymoGenetics has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock to cover overallotments, if any. The offering is expected to close on or about January 12, 2010, subject to satisfaction of customary closing conditions. Leerink Swann LLC is acting as sole book-running manager for the offering. Wedbush Morgan Securities, Inc., William Blair & Company, L.L.C., Canaccord Adams Inc. and McAdams Wright Ragen, Inc. are acting as co-managers for the offering.
|
|
|
|
|
|
|
|
|
|
|